Sendero Wealth Management LLC Raises Stock Holdings in Johnson & Johnson $JNJ

Sendero Wealth Management LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 4.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,353 shares of the company’s stock after buying an additional 337 shares during the quarter. Sendero Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,276,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the first quarter valued at about $49,000. Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson in the first quarter valued at about $52,000. Finally, Pandora Wealth Inc. purchased a new stake in Johnson & Johnson in the first quarter valued at about $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Argus set a $210.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday. Finally, Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Stock Down 1.1%

Shares of JNJ stock opened at $190.38 on Friday. The stock has a 50 day moving average of $182.26 and a 200 day moving average of $166.13. The company has a current ratio of 1.07, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market cap of $458.69 billion, a P/E ratio of 18.38, a P/E/G ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.